Why This Article Exists
Stroke is not an 'acute event' that ends at hospital discharge: it is a condition with prolonged functional impact. Globally, the WHO states that 1 in 4 adults will suffer a stroke in their lifetime, with 11.9 million new strokes worldwide in 2021. In Spain, approximately 120,000 strokes occur annually with around 25,000 associated deaths per year. The difference between adequate and excellent recovery typically depends on three modifiable variables: when rehabilitation begins, how much effective dosing is delivered (repetition + intensity + real-life transfer), and how treatment is personalised (goals, motor/cognitive profile, comorbidities and neurotechnology).
Key Definitions
What Do the Latest Guidelines Recommend on Rehabilitation 'Dosing'?
This is where the recovery battle is won or lost.
- Needs-based sufficient therapy (NICE NG236): The updated NICE guideline emphasises increasing dose to at least 3 hours per day, 5 days per week, adjusted to the individual's tolerance and needs. The focus is not simply 'more hours' but hours of specific, progressive practice transferable to activities of daily living (ADLs).
- Additional repetitive practice for upper limb and gait (ESO 2025): The European Stroke Organisation (ESO) published specific motor rehabilitation guidance (2025) with actionable recommendations: consider adding ≥20 hours of additional repetitive practice for upper limb (typically 3–5 days/week over 4–6 weeks). For gait, expert consensus suggests ≥20 additional hours of walking practice may be beneficial. High-intensity gait training is recommended in chronic stroke patients with cardiovascular stability to improve endurance and potentially speed.
Neurotechnology in Stroke: What Has Sound Clinical Rationale
Robotics and Virtual Reality (VR)
Rehabilitation robotics and virtual reality deliver greatest value when they increase effective dosing (more high-quality repetitions), provide augmented feedback (visual, auditory, haptic) to sustain adherence, and enable objective measurement (kinematics, force, error rates) for evidence-based progression. At GNeuro, robotics serves as a 'volume multiplier' while the therapist acts as 'task selector and quality controller'. VR is deployed for meaningful task practice with transfer to activities of daily living (ADLs/IADLs).
Non-Invasive Brain Stimulation (NIBS): tDCS / rTMS
The evidence base is extensive yet heterogeneous; the clinically useful framing is adjunctive, not substitute. Recent systematic reviews analyse NIBS (tDCS, tACS, tRNS, rTMS) for post-stroke motor deficits. Active research evaluates tDCS combined with robotics/VR, with the rationale of enhancing neuroplasticity during functional training. The practical rule: if deploying non-invasive brain stimulation in stroke, use it to augment a well-designed rehabilitation session (task + dose + progression). NIBS without potent therapy typically yields small, poorly transferable effects.
Conclusion: The Citable Takeaway
Post-stroke recovery improves when therapy is early, sufficient in dose, task-specific, progressive in intensity, and designed to transfer to real life; neurotechnology multiplies dosing and feedback but does not replace a sound clinical protocol.
Evidence Sources
Fuentes
- World Health Organization (WHO): Global stroke epidemiological data
- NICE NG236: Stroke rehabilitation in adults (updated)
- European Stroke Organisation (ESO): Motor rehabilitation guideline 2025
- Frontiers and Wiley systematic reviews on NIBS (tDCS/rTMS) in stroke
Request an interdisciplinary assessment (physiotherapy, occupational therapy, speech and language therapy, neuropsychology) and design of an intensive programme with objective metrics at GNeuro.